

Yokoo T, Kamimura K, Suda T, Kanefuji T, Oda M, Zhang G, Liu D, <u>Aoyagi Y.</u>	Novel electric power-driven hydrodynamic injection system for gene delivery: safety and efficacy of human factor IX delivery in rats.	Gene Therapy	20 (8)	816-823	2013
Suzuki Y, Otake T, Nishiguchi S, Hashimoto E, <u>Aoyagi Y.</u> , <u>Onji M</u> , Kohgo Y. The Japan Non-B, Non-C Liver Cirrhosis Study Group.	Survey of non-B, non-C liver cirrhosis in Japan.	Hepatol Res	43 (10)	1020-1031	2013
Takamura M, Yamagiwa S, Matsuda Y, Ichida T, <u>Aoyagi Y.</u>	Involvement of liver-intestine cadherin in cancer progression.	Med Mol Morphol	46 (1)	1-7	2013
Sakamaki A, Kamimura K, Shioji K, Sakurada J, Nakatsue T, Wada Y, Imai M, Mizuno K, Yamamoto T, Takeuchi M, Sato Y, Kobayashi M, Naito M, Narita I, <u>Aoyagi Y.</u>	Immunoglobulin g4-related disease with several inflammatory foci.	Intern Med	52	457-462	2013
Imai M, Higuchi M, Kawamura H, Yoshita M, Takahashi M, Oie M, Matsuki H, Tanaka Y, <u>Aoyagi Y</u> , Fujii M.	Human T cell leukemia virus type 2 (HTLV-2) Tax2 has a dominant activity over HTLV-1 Tax1 to immortalize human CD4(+) Tcells.	Virus Genes	46	39-46	2013
Hara Y, Sato Y, Yamamoto S, Oya H, Igarashi M, Abe S, Kokai H, Miura K, Suda T, Nomoto M, <u>Aoyagi Y</u> , Hatakeyama K.	Successful laparoscopic division of a patent ductus venosus: report of a case.	Surg Today	43 (4)	434-438	2012
Kamimura K, Nomoto M, <u>Aoyagi Y.</u>	Hepatic angiomyolipoma: diagnostic findings and management.	Int J Hepatol	2012	410781	2012
Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, <u>Aoyagi Y.</u>	Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma.	BMC Gastroenterol	12	127	2012
Oya H, Sato Y, Yamanouchi E, Yamamoto S, Hara Y, Kokai H, Sakamoto T, Miura K, Shioji K, <u>Aoyagi Y</u> , Hatakeyama K.	Magnetic compression anastomosis for bile duct stenosis after donor left hepatectomy: a case report.	Transplant Proc	44	806-809	2012

Fukuhara Y, Suda T, Kobayashi M, Tamura Y, Igarashi M, Waguri N, Kawai H, <u>Aoyagi Y.</u>	Identification of cellular genes showing differential expression associated with hepatitis B virus infection.	World J Hepatol	4	139-148	2012
Osaki A, Suda T, Waguri N, Ishikawa T, Yokoo T, Kamimura K, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, <u>Aoyagi Y.</u>	Formula to Predict Platelet Count after Partial Splenic Arterial Embolization in Patients with Hypersplenism.	J Vasc Interv Radiol	23	900-907	2012
Go R, Takizawa K, Hirose S, Katsuragi Y, <u>Aoyagi Y.</u> , Mishima Y, Kominami R..	Impairment in differentiation and cell cycle of thymocytes by loss of a Bcl11b tumor suppressor allele that contributes to leukemogenesis.	Leuk Res	36	1035-1040	2012
Tsuchiya A, Imai M, Kamimura H, Takamura M, Yamagiwa S, Sugiyama T, Nomoto M, Heike T, Nagasawa T, Nakahata T, <u>Aoyagi Y.</u>	Increased Susceptibility to Severe Chronic Liver Damage in CXCR4 Conditional Knock- Out Mice.	Dig Dis Sci	57	2892-2900	2012
Miyake Y, <u>Yamamoto K.</u>	Role of gut microbiota in liver diseases.	Hepatol Res	43	139-146	2013
Ohnishi A, Miyake Y, Matsushita H, Matsumoto K, Takaki A, Yasunaka T, Koike K, Ikeda F, Shiraha H, Nouso K, <u>Yamamoto K.</u>	Serum levels of soluble adhesion molecules as prognostic factors for acute liver failure.	Digestion	86	122-128	2012
Miyake Y, Yasunaka T, Ikeda F, Takaki A, Nouso K, <u>Yamamoto K.</u>	SIRS score reflects clinical features of non-acetaminophen-related acute liver failure with hepatic coma.	Intern Med	51	823-828	2012
Matsuda H, Ito Y, Suto H, Yamakawa A, Satomi S, Ohtani M, Yamazaki Y, Kusaka Y, Shimabukuro Y, Kikuchi K, Keida Y, Azuma T, <u>Nakamoto Y.</u>	Clinical relevance and sequence analysis of the Helicobacter pylori dupA region from two areas in Japan with different gastric cancer risks.	Immuno-Gastroenterology	1 (2)	127-135	2012
Marukawa Y, <u>Nakamoto Y.</u> , Kakinoki K, Tsuchiyama T, Iida N, Kagaya T, Sakai Y, Naito M, Mukaida N, Kaneko S.	Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma.	Cancer Gene Ther	19 (5)	312-319	2012
Miwa S, Nishida H, Tanzawa Y, Takata M, Takeuchi A, Yamamoto N, Shirai T, Hayashi K, Kimura H, Igarashi K,	TNF- α and Tumor Lysate Promote the Maturation of Dendritic Cells for Immunotherapy for Advanced Malignant Bone and Soft Tissue Tumors.	PLoS One	7 (12)	e52926	2012

Mizukoshi E, Nakamoto Y, Kaneko S, Tsuchiya H					
Iwamoto S, Kido M, Aoki N, Nishiura H, Maruoka R, Ikeda A, Okazaki T, Chiba T, Watanabe N.	Interleukin-21 and TNF- α are critical for the development of autoimmune gastritis in mice.	J Gastroenterol Hepatol	28 (6)	982-991	2013
Iwamoto S, Kido M, Aoki N, Nishiura H, Maruoka R, Ikeda A, Okazaki T, Chiba T, Watanabe N.	TNF- α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression.	Clin Immunol	146	15-25	2013
Iwamoto S, Kido M, Aoki N, Nishiura H, Maruoka R, Ikeda A, Okazaki T, Chiba T, Watanabe N.	IFN- γ is reciprocally involved in the concurrent development of organ-specific autoimmunity in the liver and stomach.	Autoimmunity	45	186-198	2012
十河 剛, 角田知之, 川本愛里, 小松陽樹, 乾あやの, 藤澤知雄	小児原発性硬化性胆管炎発症早期の ERCP 所見	小児外科	44	250-253	2012
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Complicated Relationships of Amino Acid Substitution in Hepatitis C Virus Core Region and IL28B Genotype Influencing Hepatocarcinogenesis.	Hepatology	56	2134-2141	2012
Suzuki F, Arase Y, <u>Suzuki Y</u> , Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayabashi M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan.	J Gastroenterol	47	814-822	2012
Suzuki F, Sezaki H, Akuta N, <u>Suzuki Y</u> , Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Watahiki S, Miyakawa Y, Kumada H.	Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.	J Clin Virol	54	352-354	2012
Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S,	Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients.	J Hepatol	57	508-514	2012

Mineta R, Kumada H.					
Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, <u>Suzuki Y</u> , Arase Y, Ikeda K, Kobayashi M, Kumada H.	Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.	J Gastroenterol	47	1022-1029	2012
Arase Y, Kawamura Y, <u>Suzuki Y</u> , Suzuki F, Akuta N, Matsumoto N, Seko Y, Sezaki H, Kobayashi M, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Efficacy of reduction therapy of natural human β -interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.	Hepatol Res	42	949-957	2012
Matsumoto A, Tanaka E, <u>Suzuki Y</u> , Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsuhashi H, Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saitoh M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos (t) ide analogs in patients with chronic hepatitis B.	Hepatol Res	42	139-149	2012
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Association of IL28B Genotype and Viral Response of Hepatitis C Virus Genotype 2 to Interferon Plus Ribavirin Combination Therapy.	J Med Virol	84	1593-1599	2012
Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.	J Med Virol	84	1199-1207	2012
Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.	J Med Virol	84	1097-1105	2012

Matsumoto N, Arase Y, Seko Y, Imai N, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, <u>Suzuki Y</u> , Saitoh S, Suzuki F, Ikeda K, Kumada H, Aida K, Kobayashi T.	Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of < 126 mg/dl.	Hepatol Res	42	558-563	2012
Imai N, Ikeda K, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, <u>Suzuki Y</u> , Arase Y, Kumada H.	Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.	Japanese Journal of Clinic	42	175-182	2012
Arase Y, Kobayashi M, Suzuki F, <u>Suzuki Y</u> , Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N, Saitoh S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Hsieh SD, Ogawa K, Tanabe M, Tsuji H, Kobayashi T.	Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients.	Hepatol Res	42	264-272	2012
Arase Y, Kobayashi M, Suzuki F, <u>Suzuki Y</u> , Kawamura Y, Akuta N, Kobayashi M, Sezaki H, Saitoh S, Hosaka T, Ikeda K, Kumada H, Kobayashi T.	Effect of type 2 diabetes on risk for malignancies included hepatocellular carcinoma in chronic hepatitis C.	Hepatology	57 (3)	964-973	2012
田中榮司, 松本晶博, <u>鈴木義之</u> , 小林万利子, 田中靖人, 新海 登, 髭 修平, 八橋 弘, 長岡進矢, 茶山一彰, 柘植雅貴, 横須賀収, 今関文夫, 西岡修平, 斎藤正紀, 藤原 圭, 鳥居信之, 平松直樹, 狩野吉康	核酸アナログ薬中止に伴うリスク回避のための指針 2012—厚生労働省「B型肝炎の核酸アナログ薬治療における治療中止基準の作成と治療中止を目指したインターフェロン治療の有用性に関する研究」の報告—	肝臓	53 (4)	237-242	2012
今井則博, 池田健次, 瀬古裕也, 原 祐, 大野敦司, 松本直樹, 川村祐介, 保坂哲也, 小林正宏, 斎藤 聰, 瀬崎ひとみ, 芥田憲夫, 鈴木文孝, <u>鈴木義之</u> , 荒瀬康司, 熊田博光	ミリプラチン動注化学療法を併用したラジオ波凝固療法	肝臓	53 (6)	351-354	2012

原 祐, 芥田憲夫, 福島泰斗, 濑古裕也, 川村祐介, 濑崎ひとみ, 保坂哲也, 小林正宏, 斎藤 聰, 鈴木義之, 鈴木文孝, 荒瀬康司, 池田健次, 小林万利子, 熊田博光	高齢者C型慢性肝炎に対するテラプレビル 1500mg 減量投与のパイロット・スタディ	肝臓	53 (10)	624-626	2012
Harada K, Nakanuma Y,	Innate immunity in the pathogenesis of cholangiopathy, A recent update.	Inflamm Allergy Drug Targets.	11 (6)	478-483	2012
原田憲一, 中沼安二	病理像から見た IgG4 硬化性胆管炎	胆と脾	33 (6)	485-490	2012
原田憲一, 中沼安二	原発性硬化性胆管炎と IgG4 関連硬化性胆管炎の病態と線維化の異同	肝胆脾	65 (2)	343-349	2012
中沼安二, 原田憲一	自己免疫性肝炎・原発性胆汁性肝硬変・硬化性胆管炎 (IgG4 関連硬化性胆管炎を含む) の病理診断における最新の知見	最新医学	8 (67)	19-26	2012
田中 篤	UDCA 不応例の対策	日本消化器病学会雑誌	110	16-21	2013
石橋大海, 小森敦正	原発性胆汁性肝硬変 (PBC) の診療ガイドライン	Minds トピックス		on line	2013
石橋大海, 小森敦正	原発性胆汁性肝硬変 (PBC) 診療ガイドライン作成を通して	日本消化器病学会雑誌	110	1-7	2013
石橋大海, 下田慎治	原発性胆汁性肝硬変の不思議—胆管障害の機序は?	日本臨床免疫学会会誌	35	455-462	2012
Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, Ishibashi H, Hisamoto S, Niuro H, Leung PS, Ansari AA, Gershwin ME, Akashi K.	The role of natural killer (NK) and NKT cells in the loss of tolerance in murine primary biliary cirrhosis.	Clin Exp Immunol	168	279-284	2012

小森敦正, 中村 稔 , 石橋大海	わが国における非B非C型肝癌の実態— (5) PBCにおける肝癌発生. 特集—非 B非C型 肝癌—最新の知見	臨床消化器内科	27	569-574	2012
石橋大海, 中村 稔, 小森敦正, 下田慎治	肝臓領域の EBM. 原発性胆汁性肝硬変 (何か新しい考え方があるか?)	肝胆膵	64	335-341	2012
大平弘正, 原田憲一, 下田慎治, 中村 稔	PBC の最近の話題 (座談会)	日本消化器病学会雑誌	110	29-43	2013
Haruta I, Kikuchi K, Nakamura M, Hirota K, Kato H, Miyakawa H, Shibata N, Miyake Y, Hashimoto E, Shiratori K, Yagi J.	Involvement of commensal bacteria may lead to dysregulated inflammatory and autoimmune responses in a mouse model for chronic nonsuppurative destructive cholangitis.	J Clin Immunol	32	1026-1037	2012
中村 稔	PBC の疾患感受性遺伝子による病態の 解明	Jpn J Clin Immunol (日本臨床免疫学会 会誌)	35	503-510	2012
中村 稔	PBC の疾患感受性遺伝子による病態の 解明. 特集 : ゲノムワイド関連解析か らみえてきた消化器疾患	GI.Research	20	27-32	2012
Harada K, Shimoda S, Kimura Y, Sato Y, Ikeda H, Igarashi S, Ren XS, Sato H, Nakanuma Y.	Significance of immunoglobulin G4 (IgG4) -positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of IgG4 reaction in cancer tissue.	Hepatology	56	157-164	2012
Shimoda S, Selmi C, Gershwin ME.	Fractalkine and other chemokines in primary biliary cirrhosis.	Int J Hepatol	2012	102839	2012
石橋大海, 中沼安二, 上野義之, 江川裕人 , 小池和彦, 小森敦正 , 向坂彰太郎, 下田慎治, 調 憲, 錢谷幹男, 副島雄二, 竹山康章, 田中 篤, 中牟田誠 , 中村 稔, 原田憲一, 福嶋伸良, 前原喜彦, 森實敏夫, 坪内博仁	原発性胆汁性肝硬変 (PBC) の診療ガイ ドライン (2012 年)	肝臓	53	633-686	2012
Waki K, Sugawara Y, Mizuta K, Taniguchi M, Ozawa M, Hirata M, Nozawa M, Kaneko J, Takahashi K, Kadowaki T, Terasaki PI, Kokudo N.	Predicting Operational Tolerance in Pediatric Living-Donor Liver Transplantation by Absence of HLA Antibodies.	Transplantation	95	177-183	2013

Kawaguchi Y, Sugawara Y, Yamashiki N, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Nojiri K, <u>Kokudo N.</u>	Role of 6-month abstinence rule in living donor liver transplantation for patients with alcoholic liver disease.	Hepatol Res	43 (11)	1169-1174	2013
Togashi J, Sugawara Y, Akamatsu N, Tamura S, Yamashiki N, Kaneko J, Sakamoto Y, Aoki T, Hasegawa K, <u>Kokudo N.</u>	Quality of life after adult living donor liver transplantation: A longitudinal prospective follow-up study.	Hepatol Res	43 (10)	1052-1063	2013
Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, Hasegawa K, Sakamoto Y, Koike K, <u>Kokudo N.</u>	Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome.	Hepatol Res	42	1016-1023	2012
Yamashiki N, Sugawara Y, Tamura S, Nakayama N, Oketani M, Umeshita K, Uemoto S, <u>Mochida S,</u> <u>Tsubouchi H, Kokudo N.</u>	Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey.	Liver Transpl	18	1069-1077	2012
Ikegami T, Shirabe K, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Harimoto N, Toshima T, Yamashita S, Ikeda T, <u>Maehara Y.</u>	Strategies for successful left-lobe living donor liver transplantation in 250 consecutive adult cases in a single center.	J Am Coll Surg	216 (3)	353-362	2013
Soejima Y, Muto J, Matono R, Nishnomiya M, Ikeda T, Yoshizumi T, Uchiyama H, Ikegami T, Shirabe K, <u>Maehara Y.</u>	Strategic breakthrough in adult ABO-incompatible living donor liver transplantation: preliminary results of consecutive seven cases.	Clin Transplant	27 (2)	227-231	2013
Kayashima H, Shirabe K, Morita K, Hashimoto N, Ikegami T, Yosizumi T, Soejima Y, Maehara Y.	Liver regeneration and Venous Collateral Formation in the Right Lobe Living-Donor Remnant: Segmental Volumetric Analysis and Three-Dimensional Visualization.	Transplantation	95 (2)	353-360	2012
<u>Egawa H, Nakanuma Y,</u> <u>Maehara Y, Uemoto S,</u> Eguchi S, Sato Y, Shirabe K, Takatsuki M, Mori A, Yamamoto M, <u>Tsubouchi H.</u>	Disease recurrence plays a minor role as a cause for retransplantation after living-donor liver transplantation for primary biliary cirrhosis: A multicenter study in Japan.	Hepatol Res	43 (5)	502-507	2012
<u>Ueno Y.</u>	The current endeavors to understand the pathogenesis of intractable liver diseases.	Tohoku J Exp Med	226 (3)	171-175	2012
Quinn M, <u>Ueno Y,</u> Pae HY, Huang L, Frampton G, Galindo C, Francis H, Horvat D, McMillin M,	Suppression of the HPA axis during extrahepatic biliary obstruction induces cholangiocyte proliferation in the rat.	Ame J Physiol GI Liver	302 (1)	G182-193	2012

Demorow S.					
Meng F, Francis H, Glaser S, Han Y, DeMorrow S, Stokes A, Staloch D, Venter J, White M, <u>Ueno Y</u> , Reid LM, Alpini G	Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration.	Hepatology	55 (1)	209-221	2012
Francis HL, Demorow S, Franchitto A, Venter JK, Mancinelli RA, White MA, Meng F, Ueno Y, Carpino G, Renzi A, Baker KK, Shine HE, Francis TC, Gaudio E, Alpini GD, Onori P.	Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms.	Lab Invest	92 (2)	282-294	2012
Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, <u>Saibara T</u> ; JSG-NAFLD.	Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.	J Gastroenterol	47	586-595	2012
Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, <u>Saibara T</u> , Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Okanoue T.	Genetic Polymorphisms of the Human PNPLA3 Gene Are Strongly Associated with Severity of Non-Alcoholic Fatty Liver Disease in Japanese.	PLoS One	7	e38322.	2012
Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, <u>Saibara T</u> , Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T, JSG-NAFLD.	Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.	BMC Gastroenterol	12	2	2012
Yasui K, Hashimoto E, Tokushige K, Koike K, Shima T, Kanbara Y, <u>Saibara T</u> , Uto H, Takami S, Kawanaka M, Komorizono Y,	Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.	Hepatol Res	42	767-773	2012

Okanoue T: The Japan NASH Study Group.					
Masuda K, Ono M, Fukumoto M, Hirose A, Munekage K, Ochi T, Okamoto N, Akagi N, Ogawa Y, <u>Saibara T.</u>	Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease.	Hepatol Res	42	273-279	2012
Ono M, <u>Saibara T</u>	Is impaired Kupffer cell function really important to the pathogenesis of nonalcoholic steatohepatitis?	J Gastroenterol Hepatol	27	622-624	2012
Taniuchi K, Yokotani K, <u>Saibara T.</u>	BART inhibits pancreatic cancer cell invasion by PKC alpha inactivation through binding to ANX7.	PLoS One	7	e35674	2012
Taniuchi K, Yokotani K, <u>Saibara T.</u>	BART inhibits pancreatic cancer cell invasion by Rac1 inactivation through direct binding to active Rac1.	Neoplasia	12	440-450	2012
Viet Do HT, Toda K, <u>Saibara T</u> , Yagi T.	Abnormality in expression levels of gluconeogenesis-related genes by high-dose supplementation with pyridoxamine in mice.	Int J Vitam Nutr Res	82	34-40	2012
Toda K, Ono M, Yuhki K, Ushikubi F, <u>Saibara T.</u>	17beta-Estradiol is critical for the preovulatory induction of prostaglandin E2 synthesis in mice.	Mol Cell Endocrinol	362	176-182	2012
西原利治, 湯川晋弘, 腰山裕一, 小野正文	糖尿病と NASH/NAFLD	肝胆脾	65	803-808	2012
西本正子, 越智経浩, 西原利治	NAFLD/NASH の疫学～小児と成人における相違～	医薬ジャーナル	48	63-68	2012
小野正文, 岡本宣人, 西原利治	NASH 患者からの肝癌発症の頻度と危険因子	肝胆脾	65	1023-1028	2012
Fujiwara K, <u>Yokosuka O.</u>	Frequent detection of IgM anti-herpes simplex viral antibody in patients with primary biliary cirrhosis.	Hepatology	56	395	2012
藤原慶一, 横須賀收, 織田成人, 荒田慎寿, 井上和明, 滝川康裕, 井戸章雄, 持田智, 坪内博仁:「難治性の肝・胆道疾患に関する調査研究」班 劇症肝	急性肝不全に対する血液浄化療法の有効性評価:急性肝不全に対する人工肝補助療法の現状に関するアンケート調査報告	肝臓	53	530-533	2012

炎分科会 血液浄化法の有効性評価を目的としたワーキンググループ					
Miyamura T, Ishii K, Kanda T, Tawada A, Sekimoto T, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, Kiayohara T, Wakita T, <u>Yokosuka O.</u>	Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan: Recent trend of hepatitis A causing acute liver failure.	Hepatol Res	42	248-253	2012
藤原慶一, 神田達郎, <u>横須賀收</u>	A型肝炎のウイルス学	化学療法の領域増刊号 (ウイルス 肝炎のすべて)		58-66	2012
Ishibashi H, Maruyama H, Takahashi M, Shimada T, Kamesaki H, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Demonstration of intrahepatic accumulated microbubble on ultrasound represents the grade of hepatic fibrosis.	Eur Radiol	22	1083-1090	2012
Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, <u>Yokosuka O.</u>	Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.	J Viral Hepat	19	97-104	2012
Wakamatsu T, Kanda T, Tawada A, Miyamura T, Takahashi M, Chiba T, Arai M, Maruyama H, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Acute liver failure in an antimitochondrial antibody-positive 63-year-old man.	Case Rep Gastroenterol	6	394-399	2012
Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.	Viruses	4	1264-1278	2012
Kanda T, Nakamoto S, Nishino T, Takada N, Tsubota A, Kato K, Miyamura T, Maruoka D, Wu S, Tanaka T, Arai M, Mikami S, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy.	Int J Med Sci	10	43-49	2013
Takase HM, Itoh T, Ino S, Wang T, Koji T, Akira S, Takikawa Y, Miyajima A.	FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration.	Genes & Development	27	169-181	2013
Takikawa Y, Miyamoto Y, Onodera M, Kuroda H, Kasai K, Miyasaka A, Okamoto H, Takahashi M, Suzuki K.	A case with icteric acute hepatitis E with no response of IgM class anti-HEV antibody.	Hepatol Res	42	1196-1199	2012

Wang T, Takikawa Y, Sawara K, Yoshida Y, <u>Suzuki K.</u>	Negative regulation of human astrocytes by Interferon (IFN) α in relation to growth inhibition and impaired glucose utilization.	Neurochem Res	37	1898-1905	2012
Wang T, Takikawa Y, Tabuchi T, Kosaka K, Satoh T, <u>Suzuki K.</u>	Carnosic acid prevents lipid accumulation in hepatocytes through EGF/MAPK pathway.	J Gastroenterol	47	805-813	2012
鈴木一幸	肝性脳症	Medicina	7	1170-1173	2012
滝川康裕, 宮本康弘	肝胆膵領域の EBM Update2012 創症肝炎 急性肝不全	肝胆膵	64	297-307	2012
滝川康裕	重症肝炎克服に向けた取り組み	岩手医誌	63	343-349	2012
Shimizu M, Shirakami Y, Sakai H, Iwasa J, Shiraki M, Takai K, Naiki T, <u>Moriwaki H.</u>	Combination of acyclic retinoid with branched-chain amino acids inhibits xenograft growth of human hepatoma cells in nude mice.	Hepatol Res	42	1241-1247	2012
Terakura D, Shimizu M, Iwasa J, Baba A, Kochi T, Ohno T, Kubota M, Shirakami Y, Shiraki M, Takai K, Tsurumi H, Tanaka T, <u>Moriwaki H.</u>	Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice.	Carcinogenesis	33	2499-2506	2012
Shimizu M, Imai K, Takai K, <u>Moriwaki H.</u>	Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: Basic aspects, clinical applications, and future prospects.	Curr Cancer Drug Targets	12	1119-1128	2012
Shimizu M, Shirakami Y, Imai K, Takai K, <u>Moriwaki H.</u>	Acyclic retinoid in chemoprevention of hepatocellular carcinoma: targeting phosphorylated retinoid X receptor- α for prevention of liver carcinogenesis.	J Carcinog	11	11	2012
Shimizu M, Kubota M, Tanaka T, <u>Moriwaki H.</u>	Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis.	Int J Mol Sci	13	579-595	2012
Ohno T, Shirakami Y, Shimizu M, Kubota M, Sakai H, Yasuda Y, Kochi T, Tsurumi H, <u>Moriwaki H.</u>	Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand.	Cancer Lett	323	215-222	2012
Suzuki K, Endo R, Kohgo Y, Ohtake T, Ueno Y, Kato A, Suzuki K, Shiraki R,	Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma.	Hepatol Res	42	621-626	2012

Moriwaki H, Habu D, Saito M, Nishiguchi S, Katayama K, Sakaida I; for the Japanese Nutritional Study Group for Liver Cirrhosis 2008.					
Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, Hiroishi K, Nishiguchi S, <u>Moriwaki H</u> , Yamamoto K, Sata M, Obi S, Miyayama S, Imai Y.	Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update.	Hepatol Res	42	523-542	2012
Ninomiya S, Shimizu M, Imai K, Takai K, Shiraki M, Hara T, Tsurumi H, Ishizaki S, <u>Moriwaki H</u> .	Possible role of visfatin in hepatoma progression and the effects of branched- chain amino acids on visfatin-induced proliferation in human hepatoma cells.	Cancer Prev Res	4	2092-2100	2011
Watanabe N, Takai K, Imai K, Shimizu M, Naiki T, Nagaki M, <u>Moriwaki H</u> .	Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment.	J Clin Biochem Nutr	49	153-158	2011
Sato S, Genda T, Hirano K, Tsuzura H, Narita Y, Kanemitsu Y, Kikuchi T, Iijima K, Wada R, <u>Ichida T</u> .	Up-regulated aldo-keto reductase family1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.	Liver Int	32	1382-1390	2012
Marubashi S, Umeshita K, Asahara T, Fujiwara K, Haga H, Hashimoto T, Hatakeyama K, <u>Ichida T</u> , Kanematsu T, Kitajima M, Kiyosawa K, Makuuchi M, Miyagawa S, Satomi S, Soejima Y, Takada Y, Tanaka N, Teraoka S, Monden M.	Steroid-free living donor liver transplantation for HCV - a multicenter prospective cohort study in Japan.	Clin Transplant	26	857-867	2012
玄田拓哉, <u>市田隆文</u>	原発性胆汁性肝硬変に対する肝移植	日本消化器病学会雑誌	110	22-28	2013
Hikita H, Kodama T, Shimizu S, Li W, Shigekawa M, Tanaka S, Hosui A, Miyagi T,	Bak deficiency inhibits liver carcinogenesis: a causal link between apoptosis and carcinogenesis.	J Hepatol	57	92-100	2012

Tatsumi T, Kanto T, Hiramatsu N, Morii E, Hayashi N, <u>Takehara T.</u>					
Shimizu S, <u>Takehara T.</u> , Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.	Inhibition of autophagy potentiates the anti-tumor effect of the multi-kinase inhibitor sorafenib in hepatocellular carcinoma.	Int J Cancer	131	548-557	2012
Oketani M, <u>Ido A</u> , Uto H, <u>Tsubouchi H.</u>	Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy.	Hepatol Res	42 (7)	627-636	2012
井上和明, 五味邦代, 与芝真彰	劇症肝炎	検査と技術	40 (10, 増刊 号)	884-890	2012
井上和明	サイクロフィリンインヒビターの今後の展開について	肝臓	53 (Suppl.1)	A148	2012
井上和明	劇症肝炎成因不明例における肝細胞破壊機序の免疫学的検討	肝臓	53 (Suppl.1)	A311	2012
井上和明, 与芝真彰	劇症肝炎成因不明例の検討	肝臓	53 (7)	447-448	2012
井上和明, 五味邦代, 与芝真彰	劇症肝炎超急性型から考える内科治療の意義と肝移植の時期とシステムの問題点	肝臓	53 (7)	451	2012
井上和明, 与芝真彰	成因から考える治療 移植医療との連携	肝臓	53 (Suppl.2)	A624	2012
五味邦代, <u>井上和明</u> , 与芝真彰	超急性の経過をとるB型劇症肝炎の検討	肝臓	53 (Suppl.3)	A822	2012
猪 聰志, <u>井上和明</u> , 与芝真彰	劇症肝炎 成因不明例の検討	肝臓	53 (Suppl.3)	A829	2012
黒田高明, 田上 靖, 下田浩輝, 中野利香, 笹平直樹, 前川久登, 与芝真彰, <u>井上和明</u>	我々の経験した de novo B型肝炎の2例	肝臓	53 (Suppl.3)	A884	2012

<u>井上和明</u> , 与芝真彰	急性肝不全治療の進歩	人工臓器	41 (2)	S88	2012
渡邊綱正, <u>井上和明</u> , 田中靖人	血小板低値のC型肝炎治療	消化器の臨床	15 (3)	303-308	2012
<u>井上和明</u> , 与芝真彰	臓器移植法改正後の急性肝不全治療の実態と問題点	日腹部救急医会誌	33 (2)	316	2013
<u>井上和明</u>	劇症肝不全のバイオマーカー	ICU と CCU	37 (1)	59-67	2013
Inoue K, Yoshioka M.	Online Hemodiafiltration Is a Promising Method To Give a Greater Chance of Undergoing Transplantation.	Liver Transpl	18 (Suppl.1)	S245- S246	2012
Inoue K.	Intensive artificial liver support systems as perioeprative care in liver transplantation improves survival.	Transplantation	94 (10S)	566	2012
Inoue K.	Immune-modulatory role of artificial liver support system using huge volume of buffers.	Transplantation	94 (10S)	40	2012
荒田慎寿, 森脇義弘, 高山和久, 森本 学, 沼田和司, 田栗正隆, 森田智視, 今成秀則, 田中克明	急性肝不全に対する on-line hemodiafiltration を用いた人工肝補助療法の確立	肝臓	53	7-17	2012
Takaya, H. Uemura, M. Fujimura, Y. Matsumoto, M. Matsuyama, T. Kato, S. Morioka, C. Ishizashi, H. Hori, Y. Fujimoto, M. Tsujimoto, T. Kawaratani, H. Toyohara, M. Kurumatani, N. Fukui, H.	ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End- Stage Liver Disease score.	Hepatol Res	42 (5)	459-472	2012
高谷広章, 植村正人 松山友美, 石川昌利 藤本正男, 森岡千恵 辻本達寛, 瓦谷英人 福井 博, 松本雅則 藤村吉博	アルコール性肝炎における ADAMTS13 活性の動態	アルコールと医学生物学	31	57-65	2012

高谷広章, 植村正人 藤本正男, 松山友美 森岡千恵, 石川昌利 辻本達寛, 瓦谷英人 松本雅則, 藤村吉博 福井 博	肝不全における血漿エンドトキシン濃度と ADAMTS13 活性の動態	エンドトキシン・自然免疫研究	14	61-65	2011
田妻 進	2 次性硬化性胆管炎	胆と脾	33	475-478	2012
田妻 進	検診における胆道疾患の取り扱い～胆石症診療ガイドラインに基づく胆道がんへの取り組み～	日本消化器がん検診学会雑誌	50	415-420	2012
Ikegami T, Hyogo, Honda A, Miyazaki T, Y. Matsuzaki, <u>Tazuma S</u>	Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease.	J Gastroenterology	47	1257-1266	2012
Yokobayashi K, Matsushima M, Fujimura Y, <u>Tazuma S</u>	Retrospective cohort study of the incidence and risk of fever in elderly people living at home: A pragmatic aspect of home medical management in Japan.	Geriatr Gerontol Int	13 (4)	887-893	2012
Ohara H, Okazaki K, <u>Tsubouchi H</u> , Inui K, Kawa S, Kamisawa T, <u>Tazuma S</u> , Uchida K, Hirano K, Yoshida H, Nishino T, Ko SB, Mizuno N, Hamano H, Kanno A, Notohara K, Hasebe O, Nakazawa T, <u>Nakanuma Y</u> , <u>Takikawa H</u> .	Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012.	J Hepatobiliary Pancreat Sci	19	536-542	2012
小泉 大, 兼田裕司, 俵藤正信, 清水 敦, <u>佐田尚宏</u> , 安田是和	術中胆道損傷に対する胆囊管切開による3管 合流部アプローチを用いた Cチューブドレナージ術	手術	66	471-474	2012
Inoue Y, Hayashi M, Komeda K, Masubuchi S, Yamamoto M, Yamana H, Kayano H, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Takeshita A, Shibayama Y, <u>Uchiyama K</u> .	Resection Margin with Anatomic or Nonanatomic Hepatectomy for Liver Metastasis from Colorectal Cancer.	Gastrointest Surg	16	1171-1180	2012
内山和久	最新の肝癌手術 系統的肝切除のための工夫	大阪医科大学雑誌	71	9-13	2012

井上善博, <u>内山和久</u>	3D シュミレーション・ナビゲーションによるグリソン先行処理肝切除の実際	胆と脾	34	35-41	2013
<u>Tsuyuguchi T,</u> Sugiyama H, Sakai Y, Nishikawa T, <u>Yokosuka O</u> , Mayumi T, Kiriyama S, Yokoe M, Takada T.	Prognostic factors of acute cholangitis in cases managed using the Tokyo Guidelines.	J Hepatobiliary Pancreat Sci	19	557-565	2012
<u>Nakanuma Y</u> , Sato Y, Ikeda H, Harada K, Kobayashi M, Sano K, Uehara T, Yamamoto M, Ariizumi S, Park YN, Choi JH, Yu E.	Intrahepatic Cholangiocarcinoma With Predominant "Ductal Plate Malformation" Pattern: A New Subtype.	Am J Surg Pathol	36	1629-1635	2012
Matsubara T, Sato Y, Sasaki M, Harada K, Nomoto K, Tsuneyama K, Nakamura K, Gabata T, Matsui O, <u>Nakanuma Y.</u>	Immunohistochemical characteristics and malignant progression of hepatic cystic neoplasms in comparison with pancreatic counterparts.	Hum Pathol	43	2177-2186	2012
Kimura Y, Harada K, <u>Nakanuma Y.</u>	Pathologic significance of immunoglobulin G4-positive plasma cells in extrahepatic cholangiocarcinoma.	Hum Pathol	43	2149-2156	2012
Igarashi S, Matsubara T, Harada K, Ikeda H, Sato Y, Sasaki M, Matsui O, <u>Nakanuma Y.</u>	Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.	Histopathology	61	266-276	2012
Xu J, Igarashi S, Sasaki M, Matsubara T, Yoneda N, Kozaka K, Ikeda H, Kim J, Yu E, Matsui O, <u>Nakanuma Y.</u>	Intrahepatic cholangiocarcinomas in cirrhosis are hypervascular in comparison with those in normal livers.	Liver Int	32	1156-1164	2012
Harada K, Shimoda S, Kimura Y, Sato Y, Ikeda H, Igarashi S, Ren XS, Sato H, <u>Nakanuma Y.</u>	Significance of IgG4-positive cells in extrahepatic cholangiocarcinoma: Molecular mechanism of IgG4 reaction in cancer tissue.	Hepatology	56	157-164	2012
<u>中沼安二</u> .	肝内胆管癌の腫瘍分類—最近の展開、新たな提案を踏まえて	日本消化器病学会雑誌	109	1865-1871	2012
<u>中沼安二</u> , 佐藤保則, 中西喜嗣.	分枝型胆管内乳頭状腫瘍 (IPNB,branch type) : その病理学的特徴と発生・進展機序	胆道	26	592-598	2012

<u>中沼安二</u>	膵癌・胆道癌—診断・治療 Q&A. IPNB (胆管内乳頭状腫瘍)について詳しく教えてください	膵・胆道癌 FRONTIER	2	34-37	2012
佐藤保則, <u>中沼安二</u>	胆管内上皮性腫瘍 BillN と癌化	肝胆膵	65	503-510	2012
中西喜嗣, 大原正範, <u>中沼安二</u> , 新田健雄, 平野 聰.	胆管付属腺に発生する IPNB と悪性化	肝胆膵	65	495-502	2012
<u>中沼安二</u> , 原田憲一, 佐藤保則, 丸藤ちひろ, 五十嵐沙耶, 池田博子.	胆道癌幹細胞の同定と臨床的意義—胆管周囲 付属腺のインパクト—	肝胆膵	65	95-105	2012
佐々木素子, <u>中沼安二</u>	胆・膵腫瘍の分子病理診断.	最新医学	3	405-411	2012
<u>正田純一</u>	肝疾患と分子スポーツ医学	医学のあゆみ	24410	934-938	2013
<u>正田純一</u>	胆石と胆囊がん	胆道	26	205-211	2012
Yamanashi Y, Takada T, <u>Shoda J</u> , Suzuki H.	Novel Function of Niemann-Pick C1-Like 1as a Negative Regulator of Niemann-Pick C2Protein.	Hepatology	55	953-964	2012
Onuki K, Sugiyama H, Ishige K, Kawamoto T, Ota T, Ariizumi S, Yamato M, Kadota S, Takeuchi K, Ishikawa A, Onodera M, Onizawa K, Yamamoto M, Miyoshi E, <u>Shoda J</u> .	Expression of N-acetylglucosaminyltransferase V in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.	J Gastroenterol		In press	
Onuki K, <u>Shoda J</u> , Kawamoto T, Ariizumi S, Yamamoto M.	Expression of N-acetylglucosaminyltransferase V in intrahepatic cholangiocarcinoma and its association with clinical findings.	Tokyo Joshi Kadaigaku Zasshi	82	62-69	2012
佐藤巳喜夫, 海老沼次男, 松尾亮太, 佐々木亮孝, 大河内信弘, 森下由紀雄, 野口雅之, <u>正田純一</u> , 兵頭一之介	総胆管結石内視鏡治療 1年後に発見された上部胆管早期癌の1例	胆道	26	749-755	2012

Okada K, Warabi E, Sugimoto H, Horie M, Gotoh N, Tokushige K, Hashimoto E, Utsunomiya H, Takahashi H, Ishii T, Yamamoto M, <u>Shoda J.</u>	Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet.	J Gastroenterol	48 (5)	620-632	2013
Mizukoshi E, Fushimi K, Arai K, Yamashita T, <u>Honda M</u> , Kaneko S.	Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma.	Liver Int	32 (10)	1516-1526	2012
Okada H, <u>Honda M</u> , Campbell JS, Sakai Y, Yamashita T, Takeuchi Y, Hada K, Shirasaki T, Takabatake R, Nakamura M, Sunagozaka H, Tanaka T, Fausto N, Kaneko S.	Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development.	Cancer Res	72 (17)	4459-4471	2012
Mizuno H, <u>Honda M</u> , Shirasaki T, Yamashita T, Yamashita T, Mizukoshi E, Kaneko S.	Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma.	Liver Int	32 (7)	1146-1155	2012

研究成果の刊行に関する一覧表（平成25年度）

書籍

著者名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ
錢谷幹男	消化器・肝胆膵疾患における自己抗体検査	浜窪隆夫	新機能抗体開発ハンドブック	エヌ・ティー・エス	東京	2012	470-476
錢谷幹男	自己免疫性肝炎	矢崎義雄	内科学	朝倉書店	東京	2013	1131-1133
阿部雅則, <u>恩地森一</u>	自己免疫性肝炎	小川聰	内科学書 改訂第8版	中山書店	東京	2013	271-274
阿部雅則, <u>恩地森一</u>	自己免疫性肝炎	北村聖	臨床病態学2(第2版)	ヌーヴェルヒロカワ	東京	2013	126-128
原田憲一	III章：非腫瘍疾患 ・自己免疫性肝炎 ・原発性硬化性胆管炎 ・その他の二次性硬化性胆管炎、胆管系疾患	中沼安二	肝臓を診る 医師のための肝臓病理テキスト	南江堂	東京	2013	89-94, 143-150
原田憲一, <u>中沼安二</u>	第2章 非腫瘍性胆管・胆囊疾患 ・総論：診断アプローチ ・各論：代表的な疾患	中沼安二, 坂元亨宇, 福嶋敬宜	キーワードとアルゴリズムで捉える：肝胆膵の実践病理診断	文光堂	東京	2013	41-64
<u>中沼安二</u> , 原田憲一, 池田博子	8章 消化器疾患各論 ・胆道疾患：原発性硬化性胆管炎	浅香正博, 菅野健太郎, 千葉勉	カラー版 消化器病学 -基礎と臨床-	西村書店	東京	2013	1405-1410
竹山康章, <u>向坂彰太郎</u>	原発性胆汁性肝硬変, 原発性硬化性胆管炎	田中良哉	免疫・アレルギー疾患イラストレイテッド	羊土社	東京	2013	241-247
竹山康章, <u>向坂彰太郎</u>	原発性胆汁性肝硬変	浅香正博, 菅野健太郎, 千葉勉	カラー版 消化器病学 -基礎と臨床-	西村書店	東京	2013	1209-1216
腰山裕一, 湯川晋弘, <u>西原利治</u>	メタボ肝癌の高危険群①	小俣政男	メタボ肝癌	アークメディア	東京	2013	97-101
<u>西原利治</u>	肥満症と脂肪肝、NASH	中尾一和	内分泌代謝学	診断と治療社	東京	2013	449-450